Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT ID: NCT04128501
Last Updated: 2025-10-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
125 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-05-05
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT04550442
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
+2 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
NCT04487106
Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
+3 more
COMPLETED
PHASE2
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03862157
Acute Myeloid Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Eosinophilic Leukemia, Not Otherwise Specified
+13 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT03586609
Acute Myeloid Leukemia
RECRUITING
PHASE2
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523
Acute Myeloid Leukemia (AML)
ACTIVE_NOT_RECRUITING
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
1\. To determine relapse-free survival after the use of venetoclax in combination with azacitidine given as maintenance therapy or for eradication of minimal residual disease in patients with high risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT).
SECONDARY OBJECTIVES:
1. To determine the safety and toxicity of venetoclax in combination with azacitidine (type, frequency, severity of adverse events \[AEs\] and relationship of AEs to venetoclax)
2. To determine response duration, overall survival.
3. To determine Incidence of acute and chronic graft versus host disease (GVHD)
4. To perform matched pairs analysis to obtain bias corrected treatment comparisons of Venetoclax + Vidaza (V+V) to standard therapy in AML patients with no evidence of disease (AML D-) subgroup.
EXPLORATORY OBJECTIVE:
1\. To investigate possible relationships between baseline protein and gene expression signatures/mutation profile and BH3 profiling in predicting relapse-free survival time to the combination. This exploratory analysis will be done for the data from the entire study, accounting for the noted biological variables covariates, as well as disease status and whether or not the patient had AML, by fitting a Bayesian time-to-event regression model with RFS the outcome variable.
OUTLINE:
Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine subcutaneously (SC) on days 1-5 and venetoclax orally (PO) once daily (QD) on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
1\. To determine relapse-free survival after the use of venetoclax in combination with azacitidine given as maintenance therapy or for eradication of minimal residual disease in patients with high risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT).
SECONDARY OBJECTIVES:
1. To determine the safety and toxicity of venetoclax in combination with azacitidine (type, frequency, severity of adverse events \[AEs\] and relationship of AEs to venetoclax)
2. To determine response duration, overall survival.
3. To determine Incidence of acute and chronic graft versus host disease (GVHD)
4. To perform matched pairs analysis to obtain bias corrected treatment comparisons of Venetoclax + Vidaza (V+V) to standard therapy in AML patients with no evidence of disease (AML D-) subgroup.
EXPLORATORY OBJECTIVE:
1\. To investigate possible relationships between baseline protein and gene expression signatures/mutation profile and BH3 profiling in predicting relapse-free survival time to the combination. This exploratory analysis will be done for the data from the entire study, accounting for the noted biological variables covariates, as well as disease status and whether or not the patient had AML, by fitting a Bayesian time-to-event regression model with RFS the outcome variable.
OUTLINE:
Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine subcutaneously (SC) on days 1-5 and venetoclax orally (PO) once daily (QD) on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Bilineal Leukemia
Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia
Therapy-Related Acute Myeloid Leukemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (azacitidine, venetoclax)
Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Azacitidine
Intervention Type
DRUG
Given SC
Venetoclax
Intervention Type
DRUG
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azacitidine
Given SC
Intervention Type
DRUG
Venetoclax
Given PO
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
5 AZC
5-AC
5-Azacytidine
5-AZC
Azacytidine
Azacytidine, 5-
Ladakamycin
Mylosar
Onureg
U-18496
Vidaza
ABT-0199
ABT-199
ABT199
GDC-0199
RG7601
Venclexta
Venclyxto
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participants 18 to 75 years of age.
2. English and non-English speaking patients are eligible.
3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.
1. AML if they had at least one of the following disease characteristics:
* Therapy related AML.
* Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML (see Appendix A.).
* Primary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis.
* Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT.
* Presence of active disease defined as bone marrow blast count \>5% at the time of HSCT.
* Participants transplanted beyond first remission. OR
2. Biphenotypic or bilineage leukemia (including a myeloid component) OR mixed phenotype acute leukemia (MPAL) OR
3. Participants with acute lymphoblastic leukemia; B cell or T cell in original.
4. Participants in morphological remission with no detectable minimal residual disase (MRD) after transplant
5. Participants who are in remission with no detectable minimal residual disease (MRD) after allogeneic stem cell transplant should have:
1. Adequate engraftment within 14 days prior to starting study drug:
2. Absolute neutrophil count (ANC) \>/= 1.0 x 109/L without daily use of myeloid growth factor (G-CSF) for at least 7 days; and,
3. Platelet \>/= 30 x 109/L without platelet transfusion within 1 week
4. Be able to start the drug therapy between 42 to 100 days following HSCT.
6. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:
1. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR
2. Myeloablative regimens including:
* Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
* Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
7. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.
8. ECOG performance status of 0, 1, or 2.
9. Serum creatinine \</=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation\*
10. Serum bilirubin \</= 1.5 x upper limit of normal (ULN).
11. Aspartate transaminase (AST) or alanine transaminase (ALT) \</= 2.5 x ULN.
12. Alkaline phosphatase \</= 2.5 x UL.
13. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
14. Negative serum or urine pregnancy test for women with reproductive potential. The only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for \> 12 months) or subjects who have been surgically sterilized or otherwise proven sterile. 3.1.2. For cohort #3 and cohort #4 patients (MRD positive cohort):
<!-- -->
1. Participants 18 to 75 years of age.
2. English and non-English speaking patients are eligible.
3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow. a. AML OR b. Biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) OR c. Participants with acute lymphoblastic leukemia; B cell or T cell in original.
4. Persistence or reappearance of MRD by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.
1. When MRD is detected by flow cytometry, disease level at or above the sensitivity level of the test will be required. • MRD level at or above 0.01% for B cell ALL and T cell ALL.
• MRD level at or above 0.1% for AML and mixed phenotype acute leukemia.
2. When MRD is detected by cytogenetics, disease level at or above the sensitivity level of the test will be required.
• The limited of detection is about 0.25% for males and 0.44% for females.
3. When MRD is detected by molecular testing, disease level at or above the sensitivity level of the test will be required. • The limited of detection is 0.01%
5. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:
a. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR b. Myeloablative regimens including:
• Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
* Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
6. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.
7. ECOG performance status of 0, 1, or 2.
8. Serum creatinine \</=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation\*
9. Serum bilirubin \</= 1.5 x upper limit of normal (ULN).
10. Aspartate transaminase (AST) or alanine transaminase (ALT) \</= 2.5 x ULN.
11. Alkaline phosphatase \</= 2.5 x UL.
12. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
13. Negative serum or urine pregnancy test for women with reproductive potential. The only participants who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for \> 12 months) or subjects who have been surgically sterilized or otherwise proven sterile.
2. English and non-English speaking patients are eligible.
3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.
1. AML if they had at least one of the following disease characteristics:
* Therapy related AML.
* Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML (see Appendix A.).
* Primary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis.
* Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT.
* Presence of active disease defined as bone marrow blast count \>5% at the time of HSCT.
* Participants transplanted beyond first remission. OR
2. Biphenotypic or bilineage leukemia (including a myeloid component) OR mixed phenotype acute leukemia (MPAL) OR
3. Participants with acute lymphoblastic leukemia; B cell or T cell in original.
4. Participants in morphological remission with no detectable minimal residual disase (MRD) after transplant
5. Participants who are in remission with no detectable minimal residual disease (MRD) after allogeneic stem cell transplant should have:
1. Adequate engraftment within 14 days prior to starting study drug:
2. Absolute neutrophil count (ANC) \>/= 1.0 x 109/L without daily use of myeloid growth factor (G-CSF) for at least 7 days; and,
3. Platelet \>/= 30 x 109/L without platelet transfusion within 1 week
4. Be able to start the drug therapy between 42 to 100 days following HSCT.
6. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:
1. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR
2. Myeloablative regimens including:
* Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
* Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
7. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.
8. ECOG performance status of 0, 1, or 2.
9. Serum creatinine \</=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation\*
10. Serum bilirubin \</= 1.5 x upper limit of normal (ULN).
11. Aspartate transaminase (AST) or alanine transaminase (ALT) \</= 2.5 x ULN.
12. Alkaline phosphatase \</= 2.5 x UL.
13. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
14. Negative serum or urine pregnancy test for women with reproductive potential. The only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for \> 12 months) or subjects who have been surgically sterilized or otherwise proven sterile. 3.1.2. For cohort #3 and cohort #4 patients (MRD positive cohort):
<!-- -->
1. Participants 18 to 75 years of age.
2. English and non-English speaking patients are eligible.
3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow. a. AML OR b. Biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) OR c. Participants with acute lymphoblastic leukemia; B cell or T cell in original.
4. Persistence or reappearance of MRD by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.
1. When MRD is detected by flow cytometry, disease level at or above the sensitivity level of the test will be required. • MRD level at or above 0.01% for B cell ALL and T cell ALL.
• MRD level at or above 0.1% for AML and mixed phenotype acute leukemia.
2. When MRD is detected by cytogenetics, disease level at or above the sensitivity level of the test will be required.
• The limited of detection is about 0.25% for males and 0.44% for females.
3. When MRD is detected by molecular testing, disease level at or above the sensitivity level of the test will be required. • The limited of detection is 0.01%
5. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:
a. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR b. Myeloablative regimens including:
• Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
* Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
6. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.
7. ECOG performance status of 0, 1, or 2.
8. Serum creatinine \</=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation\*
9. Serum bilirubin \</= 1.5 x upper limit of normal (ULN).
10. Aspartate transaminase (AST) or alanine transaminase (ALT) \</= 2.5 x ULN.
11. Alkaline phosphatase \</= 2.5 x UL.
12. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
13. Negative serum or urine pregnancy test for women with reproductive potential. The only participants who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for \> 12 months) or subjects who have been surgically sterilized or otherwise proven sterile.
Exclusion Criteria
1. Active acute GVHD grade II or higher.
2. Active chronic GVHD that is extensive (see Appendix C.).
3. Uncontrolled GVHD (see Appendix C.).
4. Concurrent use of systemic immune suppressive other than calcineurin inhibitors, sirolimus and steroids
5. Active uncontrolled systemic fungal, bacterial or viral infection.
6. Active bleeding.
7. Symptomatic or uncontrolled arrhythmias.
8. Significant active cardiac disease within the previous 6 months, including:
1. New York Heart Association (NYHA) class III or IV congestive heart failure see Appendix C.).
Unstable angina or angina requiring surgical or medical intervention, and/or b. Myocardial infarction.
9. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).
10. Prior history of malignancies, other than leukemia, unless the subject has been free of the disease for \>/= 1 year. However, participants with the following history/concurrent conditions are allowed:
1. Basal or squamous cell carcinoma of the skin;
2. Carcinoma in situ of the cervix;
3. Carcinoma in situ of the breast;
4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] clinical staging system).
11. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
2. Active chronic GVHD that is extensive (see Appendix C.).
3. Uncontrolled GVHD (see Appendix C.).
4. Concurrent use of systemic immune suppressive other than calcineurin inhibitors, sirolimus and steroids
5. Active uncontrolled systemic fungal, bacterial or viral infection.
6. Active bleeding.
7. Symptomatic or uncontrolled arrhythmias.
8. Significant active cardiac disease within the previous 6 months, including:
1. New York Heart Association (NYHA) class III or IV congestive heart failure see Appendix C.).
Unstable angina or angina requiring surgical or medical intervention, and/or b. Myocardial infarction.
9. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).
10. Prior history of malignancies, other than leukemia, unless the subject has been free of the disease for \>/= 1 year. However, participants with the following history/concurrent conditions are allowed:
1. Basal or squamous cell carcinoma of the skin;
2. Carcinoma in situ of the cervix;
3. Carcinoma in situ of the breast;
4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis \[TNM\] clinical staging system).
11. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Betul Oran
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
http://www.mdanderson.org
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-06674
Identifier Type: REGISTRY
Identifier Source: secondary_id
2019-0353
Identifier Type: OTHER
Identifier Source: secondary_id
2019-0353
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
NCT04160052
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
NCT04905810
RECRUITING
PHASE2
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
NCT06773208
RECRUITING
PHASE2
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
NCT06903702
RECRUITING
PHASE2
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
NCT04809181
RECRUITING
PHASE2
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
NCT04161885
TERMINATED
PHASE3
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT04140487
RECRUITING
PHASE1/PHASE2
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
NCT04062266
ACTIVE_NOT_RECRUITING
PHASE2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
RECRUITING
PHASE2
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
NCT04867928
UNKNOWN
PHASE2
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
NCT04746235
ACTIVE_NOT_RECRUITING
PHASE2
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
NCT06686108
RECRUITING
PHASE2
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318
WITHDRAWN
PHASE1/PHASE2
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
NCT04435691
TERMINATED
PHASE1/PHASE2
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
NCT06158100
SUSPENDED
PHASE1
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
NCT07082452
NOT_YET_RECRUITING
PHASE3
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
NCT03808610
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
NCT05431257
RECRUITING
PHASE2
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261
RECRUITING
PHASE2
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
NCT04150029
TERMINATED
PHASE2
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
NCT03214562
RECRUITING
PHASE1/PHASE2
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
NCT03573024
ACTIVE_NOT_RECRUITING
PHASE2
VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
NCT06598384
NOT_YET_RECRUITING
PHASE2